Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.80 |
| ▸ | BRAF | P15056 | 8/20 | 0.80 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | KIF5B | P33176 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051701 | 0.89 | BRAF (1.00) | RAF1BRAFKDRRETKIF5B | |
| SCHEMBL15077870 | 0.73 | RAF1 (0.84) | RAF1BRAFKDRRETKIF5B | |
| SCHEMBL6300452 | 0.70 | BRAF (0.53) | RAF1BRAFKDRMAP4K4EGFR | |
| SCHEMBL22744963 | 0.69 | MAP4K4 (0.51) | MAP4K4ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL3174035 | 0.69 | HTT (0.53) | ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30358274 | 0.69 | HTT (0.53) | ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3977060 | 0.68 | EGFR (0.57) | RAF1KDREGFRALDH1A1LMNA | |
| SCHEMBL19473593 | 0.68 | KDR (0.51) | RAF1BRAFKDRRETKIF5B | |
| SCHEMBL15463594 | 0.68 | BRAF (0.66) | RAF1BRAFKDRRETKIF5B | |
| SCHEMBL20229657 | 0.67 | KDR (0.74) | RAF1BRAFKDRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | CNKSR1, NRAS, HRAS | RAF1 10/4885BRAF 8/4885KDR 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.